Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant
This pilot phase I trial studies the side effects and best dose of fructooligosaccharides in treating patients with blood cancer who are undergoing donor stem cell transplant. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells (called graft-versus-host disease). Nutritional supplements such as fructooligosaccharides may reduce the incidence of graft-versus-host disease in patients with blood cancer undergoing donor stem cell transplant.
|Condition or Disease||Intervention/Treatment||Phase|
- Conduct a dose escalation trial to determine the tolerability of the fructo-oligosaccharides prebiotic in allogeneic hematopoeitic stem cell transplant (HSCT) patients.
OUTLINE: This is a dose escalation study.
Patients receive fructooligosaccharides (FOS) orally (PO) twice daily (BID) for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity.
After completion of study treatment, patients are followed for 100 days.
Arms and Interventions
|Experimental: Supportive care (Fructooligosaccharide)
Patients receive FOS PO BID for 21 days starting at 7 days before allogeneic hematopoietic stem cell transplant in the absence of disease progression or unexpected toxicity.
Other: Laboratory Biomarker Analysis
Primary Outcome Measures
- Maximum tolerated dose defined as the ability to take 70% of all doses over 21 days [At day 21]
Will employ the Bayesian optimal interval design.
Patients included in the study will have a hematologic malignancy (any stage or grade) for which they are undergoing preparation for allogeneic HSCT; participants in the study will be restricted to those undergoing HSCT under reduced-intensity protocols 9924 and 9907
No limitations exist for type or amount of prior therapy
No restrictions or requirements will be placed on race
No restrictions will be made based on life expectancy
Patients will not be evaluated based on Eastern Cooperative Oncology Group (ECOG) or Karnofsky performance status (KPS)
No restrictions will be made based on organ or marrow function
Patients will be included only if they have the ability to understand and the willingness to sign a written informed consent document
Patients with a history of gastric bypass surgery or inflammatory bowel disease
Patients with a history of or current bowel obstruction
Patients actively enrolled on any other GVHD prevention trial
Patients with known fructose intolerance
Any physical or psychological condition that, in the opinion of the investigator, would pose unacceptable risk to the patient or raise concern that the patient would not comply with protocol procedures
Subjects may co-enroll on other investigational studies except for investigational studies whose primary aim is the prevention of GVHD
No additional restrictions exist regarding co-morbid disease or incurrent illness
Patients will be excluded from the trial if they have had a history of allergies or intolerance to fructooligosaccharides or the components of FOS including fructose and glucose
No exclusion is necessary based on the use of other concomitant medications; specifically there is no prohibition of concomitant antibiotic, antiviral or antifungal therapy; subjects may co-enroll on other investigational studies except for investigational studies whose primary aim is the prevention of GVHD
Pregnant or nursing patients will not be included in the study
Contacts and Locations
|1||Stanford University, School of Medicine||Palo Alto||California||United States||94304|
Sponsors and Collaborators
- Stanford University
- National Cancer Institute (NCI)
- Principal Investigator: Andrew Rezvani, Stanford University
- Principal Investigator: Tessa Andermann, Stanford University
Study Documents (Full-Text)None provided.